MOUNTAIN VIEW, California, September 22 /PRNewswire/ --

- Next-generation Solution Provides Open, Unified Environment for Custom Design

SAN DIEGO, September 22 /PRNewswire/ --

- High Speed Serial Display Controllers and Low Capacitance ESD Protection Devices to be Highlighted

ATLANTA, September 22 /PRNewswire/ --

- Savi Solution Links GPS, Satellite Communications and Sensors For Real-Time Visibility of Location and Security of Chemicals

Savi's SmartChain(R) Asset Management software now is being utilized by The Dow Chemical Company's Toxic Inhalation Hazard (TIH) rail tank car fleet to automatically monitor the location and security status of the hazardous materials they transport. The software solution, developed by Savi, a Lockheed Martin Company (NYSE: LMT), was announced here today at the opening of the LogiChem Conference.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080123/AQW081LOGO)

AURORA, Ontario, September 22 /PRNewswire/ --

Helix BioPharma announced today that it has received the necessary regulatory approvals to open clinical sites in Germany to expand upon its clinical trial with Topical Interferon Alpha-2b in patients with ano-genital warts, which is presently underway in Sweden.

"We are pleased to have received approval to open these additional clinical sites," said John Docherty, President of Helix BioPharma. "The opening of sites in Germany will grant us access to expanded clinical resources and a larger patient pool in order to enhance the recruitment rate of our trial."

COPENHAGEN, September 22 /PRNewswire/ --

- Summary: Genmab has Completed Recruitment of Patients in the Phase II Study of Ofatumumab in Combination With CHOP Chemotherapy

Genmab A/S (OMX: GEN) announced today it has completed recruitment of 56 previously untreated follicular non-Hodgkin's lymphoma (NHL) patients in the Phase II study of ofatumumab (HuMax-CD20(R)) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP).

"We are happy to finish enrolment in this first study with ofatumumab in front line follicular NHL patients," said Lisa N. Drakeman, Ph.D., Chief Executive Officer at Genmab. "We look forward to seeing the results of this trial."

LONDON, September 22 /PRNewswire/ -- The MS Society has been recognised as the only charity in the country to join a new awards initiative which aims to develop the talent of some of Britain's most promising medical researchers.

Today, at a service to mark the 60th anniversary of the Fulbright Treaty, the Fulbright Commission announced the first wave of new awards.

Supported by UK universities, institutes of higher education and the MS Society, the new awards will increase by 30% the scholarships it gives by 2010 to over 60. The awards aim to support the British and American higher education systems to increase the exchange of post graduate students, researchers and faculty.

TEL AVIV, Israel, September 22 /PRNewswire/ --

- Agritech's 17th International Agriculture Exhibition Will be the Ultimate Meeting Place for Offering and Finding Agricultural Solutions for all Aspects of Food Production

Agritech Israel (http://www.agritech.co.il), one of the leading international exhibitions, announced today that the theme of its 17th annual exhibition will be centered on products, solutions and technologies connected to food production.

Exhibitors consist of leading international companies and organizations that provide a wide range of agricultural solutions for various climates and needs. Apart from proven solutions that are already deployed around the world, such as:

- Irrigation systems - Fertilizers - Seeds and green houses

LUXEMBOURG, September 22 /PRNewswire/ -- Mini Movie International Channel S.A.R.L. offers unique short-film programming blocks now available for acquisition, broadcast and exhibition by Free- and Pay-TV channels, Internet outlets, mobile broadcasting companies, distributors, and content aggregators.

Specifically designed for broadcast on TV and other mainstream media, these tightly packaged blocks of short comedy films can increase the programming options of any entertainment company.

LONDON, September 22 /PRNewswire/ --

Optenet, a leading global IT security company and a provider of intelligent, integrated content security solutions, has become a member of the Internet Watch Foundation (IWF), joining over 80 member companies from a variety of organisations in their battle against illegal content online. With its web filtering expertise, Optenet aims to support the IWF's efforts to eliminate illegal Internet content, specifically, child sexual abuse images hosted anywhere in the world, as well as criminally obscene content and incitement to racial hatred content hosted in the UK.

AMSTERDAM, September 22 /PRNewswire/ -- Kiadis Pharma announced today that its lead product ATIR(TM) has been granted orphan drug designation (ODD) by the European Medicines Agency (EMEA) for the prevention of acute Graft versus Host Disease (GvHD) following an allogeneic bone marrow transplantation.

"Following the orphan drug designation granted by the FDA for our lead product ATIR(TM), this is another important milestone in the development of ATIR(TM) as a novel approach which may enable a safe and potentially life-saving mismatched bone marrow transplantation as a treatment option for end-stage blood cancer patients" says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.